Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Inks Deal For Second Alzheimer’s Test, This Time With Luminex

This article was originally published in The Pink Sheet Daily

Executive Summary

Luminex will develop a companion diagnostic for Merck’s BACE Inhibitor, MK-8931, that will test patients’ cerebrospinal fluid for the presence of two biomarkers that could indicate they are at risk of developing Alzheimer’s disease.

You may also be interested in...



TauRx Chairman Claude Wischik On Waging A Battle Against Alzheimer’s Disease His Way: An Interview With PharmAsia News (Part 2 of 2)

Claude Wischik has spent more than a decade working on a drug that would inhibit the aggregation of tau tangles in the brain, and says his work has put the Singapore-based company TauRx Pharmaceuticals Ltd. onto a path that could produce the world’s best-selling drug, surpassing Pfizer Inc.’s Lipitor (atorvastatin).

TauRx Chairman Claude Wischik On Waging A Battle Against Alzheimer’s His Way: An Interview With PharmAsia News (Part 1 of 2)

Claude Wischik has spent more than a decade working on a drug that would inhibit the aggregation of tau tangles in the brain, and says his work has put the Singapore-based company TauRx Pharmaceuticals Ltd. onto a path that could produce the world’s best-selling drug, surpassing Pfizer Inc.’s Lipitor (atorvastatin).

Merck Partners On Alzheimer’s Diagnostic With GE Healthcare

Merck will use GE Healthcare’s investigational imaging agent flutemetamol to select patients to enroll in its clinical trial studying the oral BACE inhibitor MK-8931, with a particular emphasis on a future study in Alzheimer’s patients with mild cognitive impairment.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS075392

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel